Cancer Research

Myeloma cells

Janssen seeks European approval for multiple myeloma drug

3 January 2023

Janssen has submitted a marketing authorisation application (MAA) seeking approval of talquetamab in Europe for the treatment of patients with relapsed or refractory multiple myeloma (RRMM).   Talquetamab is an investigational, off-the-shelf, bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal cells but overexpressed on myeloma cells, and CD3 […]

Patients receiving chemotherapy

Drug could prevent chemotherapy-induced hearing loss

3 January 2023

Biotechnology company Sensorion has enrolled the first patient in its Phase IIa Proof of Concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity.  Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity, or permanent and irreversible hearing loss, which occurs […]

Prostate-specific membrane antigen

New prostate cancer drug approved in Europe

22 December 2022

A new drug based on the active ingredient Lutetium-177 PSMA-617 has been approved by the European Commission for the treatment of metastatic prostate cancer carrying the surface molecule PSMA (prostate specific membrane antigen).   The drug was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg […]

Testing acidity in the lab

Acid discovery raises hopes of improved immunotherapies

20 December 2022

The acidity of tumours impairs the effectiveness of anti-cancer therapies, according to a new study that could lead to a new generation of immunotherapy treatments.  Tumours have a more acidic environment (pH 6.5) than normal, healthy tissues (pH 7.2). New research has shown for the first time that this acidity blocks the activities of cytokines. […]

Multiple myeloma

Partnership will co-develop cell therapy for multiple myeloma

19 December 2022

Kite and Arcellx have entered a global strategic collaboration to co-develop and co-commercialise CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma.  Currently in Phase II clinical development, CART-ddBCMA is an investigational cell therapy product comprising autologous T cells that have been genetically modified to target multiple myeloma.  Arcellx will receive an […]

Scientist in laboratory

New trial data revealed in potential myeloma and leukaemia treatments

16 December 2022

Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia.  The findings were presented at the American Society of Hematology (ASH) 2022 Annual Meeting taking place in New Orleans, US.  Along with positive Phase II trial data for talquetamab, the company presented promising findings on the long-term results […]

First AML patient successfully transplanted with investigational drug 

15 December 2022

Vor Bio, a clinical-stage cell and genome engineering company, has announced initial clinical data from VBP101, its Phase I/IIa multicentre, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukaemia (AML).   The data observed from the first treated patient support the potential of a trem-cel transplant to be successfully […]

""

mRNA cancer vaccine meets primary efficacy endpoint

15 December 2022

Personalised mRNA vaccine mRNA-4157/V940 has demonstrated a clinically meaningful improvement in patients with late-stage melanoma.  The vaccine, in combination with Keytruda, met its primary endpoint of recurrence-free survival (RFS) for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.  Adjuvant treatment with mRNA-4157/V940, which is being developed by Moderna and Merck (MSD), […]

B-cells in multiple myeloma

Experimental immunotherapy has over 70% response rate

13 December 2022

An immunotherapy that uses a new targeted approach to kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials.  The trial results have been revealed by researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.  The therapy, known as a bispecific […]

Research scientist working in laboratory

Oncology Programme will accelerate cancer drug discovery

12 December 2022

Biometrics contract research organisation (CRO) Phastar has joined Lean Life Science’s Oncology Development Programme (ODP2).   The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.  In collaboration with global pharma companies, Cancer Research UK’s Cancer Research Horizons, Manchester Cancer Research Centre (MCRC) and […]

« Previous
Next »

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free